表紙
市場調查報告書

髓母細胞瘤 : 開發平台分析

Medulloblastoma - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 229773
出版日期 內容資訊 英文 346 Pages
訂單完成後即時交付
價格
髓母細胞瘤 : 開發平台分析 Medulloblastoma - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 346 Pages
簡介

髓母細胞瘤是兒童最常見的惡性腦腫瘤,定義上是由小腦發病。主要的症狀有早晨的頭痛,會隨著時間漸漸改善。此外還有沒有精神和噁心、步行困難、也會有失去平衡的狀況。髓母細胞瘤也會擴展到中樞神經系統的其他部位。主要的治療方法為化療、手術、生物療法、放射治療等。

本報告提供髓母細胞瘤的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,暫停中的計劃等相關資訊。

簡介

  • 調查範圍

髓母細胞瘤 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Bayer AG
  • DelMar Pharmaceuticals, Inc.
  • Ignyta, Inc.
  • Lipocure Ltd.
  • MacroGenics, Inc.
  • Medicenna Therapeutics, Inc.
  • MEI Pharma, Inc.
  • Novartis AG
  • Novogen Limited
  • Progenics Pharmaceuticals, Inc.
  • Stemline Therapeutics, Inc.
  • 武田藥品工業

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11715IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Pipeline Review, H2 2019, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 12, 10, 1, 1, 17 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 7 and 3 molecules, respectively.

Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Medulloblastoma - Overview
    • Medulloblastoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Medulloblastoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Medulloblastoma - Companies Involved in Therapeutics Development
    • Aettis Inc
    • Bayer AG
    • Biogenera SpA
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Co
    • CDG Therapeutics Inc
    • Curis Inc
    • Dalriada Therapeutics Inc
    • DelMar Pharmaceuticals Inc
    • Dracen Pharmaceuticals Inc
    • Eli Lilly and Co
    • Guangdong Zhongsheng Pharmaceutical Co Ltd
    • Immunomic Therapeutics Inc
    • IMPACT Therapeutics Inc
    • Janpix Inc
    • MacroGenics Inc
    • Mana Therapeutics Inc
    • Midatech Pharma Plc
    • MimiVax LLC
    • Moleculin Biotech LLC
    • NewLink Genetics Corp
    • Novartis AG
    • Oncoheroes Biosciences Inc
    • Ono Pharmaceutical Co Ltd
    • Oxurion NV
    • Pfizer Inc
    • Progenics Pharmaceuticals Inc
    • Sapience Therapeutics Inc
    • Senhwa Biosciences Inc
    • Shionogi & Co Ltd
    • Stemsynergy Therapeutics Inc
    • TheraBiologics Inc
    • VBI Vaccines Inc
    • Vyriad Inc
    • Y-mAbs Therapeutics Inc
  • Medulloblastoma - Drug Profiles
  • Medulloblastoma - Dormant Projects
  • Medulloblastoma - Discontinued Products
  • Medulloblastoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Medulloblastoma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Medulloblastoma - Pipeline by Aettis Inc, H2 2019
  • Medulloblastoma - Pipeline by Bayer AG, H2 2019
  • Medulloblastoma - Pipeline by Biogenera SpA, H2 2019
  • Medulloblastoma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Medulloblastoma - Dormant Projects, H2 2019
  • Medulloblastoma - Dormant Projects, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development for Medulloblastoma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019